Skip to main content

Table 5 Injection-site reactions by monthly dosing interval among pooled galcanezumab-treated participants in CGAJ and REGAIN studies, ≥1% incidence (galcanezumab exposure analysis set)

From: Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

Participants with ≥ 1 ISRs

Total, n (%)

N

1326

 IS pain

108 (8.1)

 Unspecified ISRs

103 (7.8)

 IS erythema

62 (4.7)

 IS pruritus

30 (2.3)

 IS bruising

25 (1.9)

 IS rash

18 (1.4)

 IS hematoma

14 (1.1)

  1. Abbreviations:IS injection-site, ISR injection-site reaction,  N number of galcanezumab-treated participants, n number of participants within each specific category
  2. Note: All values are for ISRs from study start up to 12 months for REGAIN and CGAJ studies; pooled galcanezumab = galcanezumab 120 mg + galcanezumab 240 mg